Bicycle Therapeutics Ltd (BCYC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $236.22M
Last updated: Nov 17, 2026 at 11:04 AM ET
Bicycle Therapeutics Ltd (BCYC) Competitors
The companies most similar to Bicycle Therapeutics are Lineage Cell Therapeutics (LCTX), Prelude Therapeutics (PRLD) and X4 Pharmaceuticals (XFOR). By market cap, Bicycle Therapeutics ranks 8th of the 13 companies on this page; Prothena Corporation (PRTA) is the largest at $419.01M.
Peer Comparison
BCYC's revenue growth of 190.2% is above the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Bicycle Therapeutics (BCYC) | $236.22M | N/A | 2.7x | -169.8% | N/A | 190.2% | 0.00% |
| Lineage Cell Therapeutics Inc (LCTX) | $231.35M | N/A | 18.7x | 16.2% | -6.7% | -61.0% | 0.00% |
| Prelude Therapeutics Inc (PRLD) | $275.32M | N/A | 16.3x | -269.7% | N/A | 41.0% | 0.00% |
| X4 Pharmaceuticals Inc (XFOR) | $318.59M | N/A | 21.7x | 0.0% | -36.9% | 63.1% | 0.00% |
| Fulcrum Therapeutics Inc (FULC) | $287.96M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Rocket Pharmaceuticals Inc (RCKT) | $256.82M | N/A | N/A | 0.0% | -2.3% | 0.0% | 0.00% |
| Inhibikase Therapeutics Inc (IKT) | $213.21M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Keros Therapeutics Inc (KROS) | $202.13M | N/A | 4.9x | -151.4% | N/A | 180.5% | 0.00% |
| Bright Minds Biosciences Inc (DRUG) | $227.96M | N/A | N/A | 0.0% | -11.2% | 0.0% | 0.00% |
| ProQR Therapeutics BV (PRQR) | $199.28M | N/A | 6.1x | -228.2% | N/A | 120.4% | 0.00% |
| Tectonic Therapeutic, Inc. (TECX) | $413.27M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Prothena Corporation plc (PRTA) | $419.01M | N/A | 7.8x | -45.4% | N/A | -74.3% | 0.00% |
| Protalix Biotherapeutics Inc (PLX) | $257.17M | 12.1x | 2.9x | 24.3% | N/A | 22.8% | 0.00% |
| Peer median | $257.00M | 12.1x | 7.8x | 0.0% | -8.9% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Bicycle Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Lineage Cell Therapeutics Inc (LCTX) | Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment... | LCTX competitors |
| Prelude Therapeutics Inc (PRLD) | Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized... | PRLD competitors |
| X4 Pharmaceuticals Inc (XFOR) | X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development... | XFOR competitors |
| Fulcrum Therapeutics Inc (FULC) | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined... | FULC competitors |
| Rocket Pharmaceuticals Inc (RCKT) | Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. | RCKT competitors |
| Inhibikase Therapeutics Inc (IKT) | Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside... | IKT competitors |
| Keros Therapeutics Inc (KROS) | Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery... | KROS competitors |
| Bright Minds Biosciences Inc (DRUG) | Bright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies... | DRUG competitors |
| ProQR Therapeutics BV (PRQR) | ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. | PRQR competitors |
| Tectonic Therapeutic, Inc. (TECX) | Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel... | TECX competitors |
| Prothena Corporation plc (PRTA) | Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases... | PRTA competitors |
| Protalix Biotherapeutics Inc (PLX) | Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its... | PLX competitors |
Frequently Asked Questions About BCYC
Who are Bicycle Therapeutics' main competitors?
The companies most similar to Bicycle Therapeutics include Lineage Cell Therapeutics (LCTX), Prelude Therapeutics (PRLD), X4 Pharmaceuticals (XFOR), Fulcrum Therapeutics (FULC) and Rocket Pharmaceuticals (RCKT), listed from the closest match.
Who is Bicycle Therapeutics' biggest competitor?
Prothena Corporation (PRTA) is the largest of the similar companies at $419.01M; Lineage Cell Therapeutics (LCTX) is the closest match by business profile, size, sector and industry.
How does BCYC stock compare with its competitors?
BCYC's P/S is 2.7x against a peer median of 7.8x; its net margin is -169.8% against a peer median of 0.0%.
Which of Bicycle Therapeutics' competitors pays a higher dividend?
Bicycle Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Bicycle Therapeutics bigger than its competitors?
No. Bicycle Therapeutics is 8th by market cap among the 13 companies on this page; the largest is Prothena Corporation (PRTA) at $419.01M.
BCYC pages: Overview, Earnings, Forecast, Financials, Competitors